Evidence map›Paper›PMID 30843122›Full record

ArticleEuropean child & adolescent psychiatry2019

Differences in the regulation of inflammatory pathways in adolescent- and adult-onset first-episode psychosis.

C Moreno, M Parellada, K S MacDowell, B García-Bueno, B Cabrera, A González-Pinto, P Saiz, A Lobo, R Rodriguez-Jimenez, E Berrocoso and 3 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in European child & adolescent psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

C MorenoChild and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense (UCM), IiSGM, Madrid, Spain. cmoreno@hggm.es.ORCID http://orcid.org/0000-0003-0541-4846
M ParelladaChild and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense (UCM), IiSGM, Madrid, Spain.
K S MacDowellDepartment of Pharmacology and Toxicology, Faculty of Medicine, UCM, Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), IUINQ, Madrid, Spain.
B García-BuenoDepartment of Pharmacology and Toxicology, Faculty of Medicine, UCM, Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), IUINQ, Madrid, Spain.
B CabreraBarcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Barcelona, Spain.
A González-PintoHospital Universitario, Alava, EHU/UPV, BIOARABA, Vitoria, Spain.
P SaizDepartment of Psychiatry, Faculty of Medicine, University of Oviedo, Oviedo, Spain.
A LoboDepartment of Psychiatry, Instituto de Investigación Sanitaria Aragón, University of Zaragoza, Zaragoza, Spain.
R Rodriguez-JimenezDepartment of Psychiatry, Instituto de Investigación Hospital, 12 de Octubre (i+12), Madrid, Spain.
E BerrocosoNeuropsychopharmacology and Psychobiology Research Group, Department of Psychology, Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz, INiBICA, University of Cádiz, Cádiz, Spain.
M BernardoBarcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, Barcelona, Spain.
J C LezaDepartment of Pharmacology and Toxicology, Faculty of Medicine, UCM, Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), IUINQ, Madrid, Spain.
From the FLAMM-PEPs study, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)
Research Institute Hospital 12 de Octubre · ESHospital General Universitario Gregorio Marañón · ESUniversidad de Oviedo · ESHospital Universitario Araba · ESUniversidad Complutense de Madrid · ESUniversidad de Cádiz · ESUniversidad de Zaragoza · ES

Funding

CIBERSAM CIBERSAM Intramural Projects 2010 (P02), ERDF Funds from the European Commission, "A way of making Europe"European Union Structural Funds and European Union Seventh Framework Program FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI)European Union Structural Funds and European Union Seventh Framework Program FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTiMISE)European Union Structural Funds and European Union Seventh Framework Program FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY)European Union Structural Funds and European Union Seventh Framework Program FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN)Government of Catalonia, Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement 2014SGR441Instituto de Salud Carlos III PI08/0208,Instituto de Salud Carlos III PI 11/00325Instituto de Salud Carlos III PI12/01303Instituto de Salud Carlos III PI14/02069Instituto de Salud Carlos III PI17/02227Madrid Regional Government B2017/BMD-3740 AGES-CM-2
6 · The paper itself

Abstract

A precise description of the inflammatory response in first-episode psychosis (FEP) by age of onset does not exist. We explored baseline and 6-month follow-up differences in the pro/anti-inflammatory balance in plasma and peripheral blood mononuclear cells in adolescent-onset FEP (≤ 18 y.o., N = 27) and adult-onset FEP (≥ 25 y.o., N = 43) using non-parametric 1-category ANCOVA, with age group as an independent variable and values of pro- and anti-inflammatory markers at baseline and at follow-up as dependent variables. We used a non-parametric repeated-measures mixed-effects model to explore the baseline/6-month change in pro- and anti-inflammatory markers within adolescent- and adult-onset groups, exploring differential trajectories of change by means of the interaction of time by age-of-onset group. Levels of the nuclear transcription factor (NFκB), a master regulator of the inflammatory and oxido/nitrosative status of cells, were higher in adolescent-onset FEP both at baseline and after 6 months. During follow-up, we found further increases in levels of soluble inflammatory markers (PGE

Indexed as

AdolescentAdultBiomarkersChildCohort StudiesFemaleHumansInflammationMalePsychotic DisordersYoung AdultBiomarkersEarly-onset psychosisInflammationInflammatory pathwaysPsychosis

Identifiers

PMID30843122
OpenAlexW2919881605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.